Ro 48-8071

Ro 48-8071 is an inhibitor of OSC (Oxidosqualene cyclase) with IC50 of appr 6.5 nM.

Product Specifications

CAS Number

[189197-69-1]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Others

Type

Reference compound

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Ro-48-8071-fumarate.html

Purity

99.13

Solubility

DMSO : ≥ 55 mg/mL|H2O : 100 mg/mL (ultrasonic)

Smiles

O=C(C1=CC=C(Br)C=C1)C2=CC=C(OCCCCCCN(C)CC=C)C=C2F.O=C(O)/C=C/C(O)=O

Molecular Formula

C27H31BrFNO6

Molecular Weight

564.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Morand OH, et al. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res. 1997 Feb;38 (2) :373-90.|[2]Liang Y, et al. Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther. 2016 May 30;9:3223-32|[3]Liang Y, et al. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat. 2014 Jul;146 (1) :51-62.|[4]Chuang JC, et al. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse. Biochem Pharmacol. 2014 Apr 1;88 (3) :351-63.